Dr. Ralph Stocker, MD – Windsor, CT
Methotrexate (MTX) therapy causes a significant decrease in soluble interlekin-2 receptors (SIL-2r) in patients with rheumatoid arthritis (RA).
Kremer, JM, Stocker, RP, Rynes, RI and Lawrence, DA, Arthritis Rheum, 1991Preliminary report of methotrexate pharmacokinetics upon initiation of therapy compared with long-term administration.
Kremer, JM, Hamilton, R, Stocker, RP and Rynes, RI, Arthritis Rheum, 1990
